Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Retained Earnings (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Retained Earnings data on record, last reported at -$274.7 million in Q3 2025.

  • For Q3 2025, Retained Earnings fell 42.54% year-over-year to -$274.7 million; the TTM value through Sep 2025 reached -$274.7 million, down 42.54%, while the annual FY2024 figure was -$199.8 million, 84842.8% down from the prior year.
  • Retained Earnings reached -$274.7 million in Q3 2025 per CAPR's latest filing, down from $1.4 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $1.4 million in Q2 2025 and bottomed at -$274.7 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$105.0 million, with a median of -$115.9 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: plummeted 178190.9% in 2024, then skyrocketed 795.28% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$101.9 million in 2021, then skyrocketed by 100.1% to $105244.0 in 2022, then skyrocketed by 124.06% to $235813.0 in 2023, then crashed by 84842.8% to -$199.8 million in 2024, then plummeted by 37.47% to -$274.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$274.7 million in Q3 2025, $1.4 million in Q2 2025, and -$224.2 million in Q1 2025.